# Radiation Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nelson Mandela (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML021-SYN
- Date: 2026-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Pieter van Zyl, MD
- Calendar frame: modern shifted

- Requested by: Thandiwe Mokoena, MD

## Reason for consultation

Man of 82 with newly diagnosed prostate adenocarcinoma, Grade Group 3, PSA 6.4 ng/mL, cT1c, NCCN unfavorable intermediate risk, found after a rising PSA on monitoring. Please advise on curative treatment, including radiotherapy with short-term androgen deprivation, and whether observation is reasonable at his age. **S**

## History

Mr. Mandela is seen at the request of Dr. Mokoena for newly diagnosed prostate cancer. A rise in PSA on routine monitoring led to an MRI and a targeted biopsy, which showed Grade Group 3 adenocarcinoma in 3 of 14 cores. He has mild urinary frequency, with an IPSS of 7, and no bone pain, weight loss, or blood in the urine. Decades ago part of his prostate was removed for benign enlargement. He had tuberculosis in the past, treated, with no symptoms since. He is independent, walks every morning, and keeps a full schedule of work and travel. He wants to understand all the options before deciding. **S**

## Examination

| System | Finding |
|---|---|
| General | Well |
| Abdomen | Soft; bladder not palpable |
| Musculoskeletal | No spinal tenderness |
| Lymph nodes | No inguinal or supraclavicular nodes |

BP 130/76 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 80.4 kg; BMI 24 kg/m². All vital signs are synthetic.

## Data reviewed

MRI prostate report and images, biopsy pathology, the first-visit PSA, testosterone, blood count, chemistry, A1c, lipids, and 25-hydroxyvitamin D, the PSMA PET/CT from two weeks ago (uptake confined to the left peripheral zone; no nodal, bone, or visceral disease), and the DXA scan from this morning (femoral neck T-score -1.4, lumbar spine -0.6). Femoral neck T-score (DXA): -1.4 (low); Lumbar spine T-score (DXA): -0.6; PHQ-2: 0. All results are synthetic.

## Assessment

1. **Prostate adenocarcinoma, cT1c N0 M0, Grade Group 3, PSA 6.4 ng/mL, NCCN unfavorable intermediate risk** (C61). I agree with the risk group: Grade Group 3 alone places him in the unfavorable intermediate group. The PSMA PET/CT shows no nodal or distant disease, so staging is complete. He is fit, and his life expectancy is estimated at about ten years, so curative treatment is reasonable. Observation, with treatment only if symptoms develop, is also a reasonable choice at his age and was discussed. Active surveillance is not recommended for Grade Group 3 disease. Radical prostatectomy is not advised at his age and after his earlier prostate operation, which raises the risk of incontinence. Brachytherapy is not advised because of the resection defect. The recommended option is external beam radiotherapy to the prostate with four to six months of androgen deprivation. **S**
2. **Short-term androgen deprivation with radiotherapy** (Z79.899). In unfavorable intermediate-risk disease, adding four to six months of androgen deprivation to radiotherapy improves cancer control. Starting it about three months before radiotherapy also shrinks the gland. A GnRH agonist with an anti-androgen for the first weeks blocks the testosterone flare. The main effects to monitor are hot flashes, fatigue, sexual effects, weight gain, bone loss, metabolic and cardiovascular risk, and changes in mood or memory. **S**
3. **Earlier prostate operation and urinary function**. The resection defect does not prevent external beam radiotherapy, but it slightly raises the risk of urinary irritation and, rarely, of a urethral stricture. Mild baseline symptoms (IPSS 7) are favorable. Moderate hypofractionation (60 Gy in 20 fractions or 70 Gy in 28) and conventional fractionation (74 to 80 Gy in 2 Gy fractions) give similar cancer control; after discussion of the shorter course and the lower dose per fraction, conventional fractionation of 74 Gy in 37 fractions was chosen. **S**
4. **Bone health before androgen deprivation**. Low bone mass at the femoral neck with mild vitamin D insufficiency. Ten-year hip fracture risk is below 3 percent, so no bone drug is needed for a six-month course. **S**

## Recommendations

1. External beam radiotherapy to the prostate and proximal seminal vesicles, 74 Gy in 37 daily fractions with intensity modulation and daily image guidance on fiducial markers; no pelvic nodal radiation.
2. Androgen deprivation for six months: bicalutamide 50 mg daily for four weeks starting today, leuprolide 22.5 mg intramuscularly in one week at this clinic and a second dose twelve weeks later, with radiotherapy starting about three months after the first injection.
3. Fiducial markers and planning CT and MRI about two weeks before radiotherapy.
4. During androgen deprivation: testosterone and PSA at three months, blood pressure and weight at every visit, hot flashes, fatigue, mood, and cognition reviewed at each visit, and glucose and lipids yearly.
5. Bone health: vitamin D 1000 units daily with a recheck in three months, calcium from food, resistance exercise, and DXA every one to two years.
6. During radiotherapy: weekly review for urinary and bowel effects; tamsulosin if urinary frequency or a weak stream develops; report blood in the urine or stool.
7. After radiotherapy: PSA six weeks after treatment, then every six months for five years and yearly after that; recurrence is a PSA rise of 2 ng/mL above the nadir (Phoenix); a temporary PSA bounce is not recurrence.

## Strengths and supports

- Supports: family, close friends, and a personal assistant who manages his schedule **S**

## Communication

Discussed with Dr. Mokoena today. The patient chose radiotherapy with six months of androgen deprivation after hearing each option, including observation, and agrees with the plan. **S**

## Follow-up

Leuprolide injection here in one week. Fiducial markers and planning in about twelve weeks. Weekly review during radiotherapy, then radiation oncology three months after treatment and every six months. Primary care manages the androgen deprivation monitoring, bone health, blood pressure, distress screening, and PSA surveillance between reviews. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208(1):10-18 (2022), American Urological Association and American Society for Radiation Oncology
- Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part III: Principles of Radiation and Future Directions. J Urol 2022;208(1):26-33 (2022), American Urological Association and American Society for Radiation Oncology
- CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026), Aether Forge
